Progress in the study of cyclic nucleotide phosphodiesterases for heart failure treatment

doi:10. 3969 / j.issn.1671-7856. 2020. 03. 020

Home > Archive>Volume 30, Issue 3, 2020 >115-120. DOI:10. 3969 / j.issn.1671-7856. 2020. 03. 020

Progress in the study of cyclic nucleotide phosphodiesterases for heart failure treatment
DOI:
                        10. 3969 / j.issn.1671-7856. 2020. 03. 020
                    
CSTR:
                        [cstr]
                    
Author:
                        SUN HuanSUN Huan
1.Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China. 2. Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun 130033. 3. Jilin Provincial Cardiovascular Research Institute, Changchun 130033
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
YU MingYU Ming
1.Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China. 2. Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun 130033. 3. Jilin Provincial Cardiovascular Research Institute, Changchun 130033
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
ZHAO QiniZHAO Qini
1.Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China. 2. Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun 130033. 3. Jilin Provincial Cardiovascular Research Institute, Changchun 130033
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
YANG PingYANG Ping
1.Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China. 2. Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun 130033. 3. Jilin Provincial Cardiovascular Research Institute, Changchun 130033
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:1.Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China. 2. Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun 130033. 3. Jilin Provincial Cardiovascular Research Institute, Changchun 130033
Clc Number:R-33
Fund Project:

Article

Figures

Metrics

Reference

Cited by

Materials

Comments

Abstract:

Heart failure is the final stage of cardiovascular disease development, and heart failure treatment strategies need to be explored. Cyclic adenosine monophosphate ( cAMP) and cyclic guanosine monophosphate ( cGMP) are second messengers that regulate signal transduction, which are hydrolyzed by a group of distributed and functional specific phosphodiesterases (PDEs) in cardiomyocytes, which play key roles in the pathogenesis of normal cell activity and heart failure. The efficacy of PDE3 and PDE5 inhibitors has been clinically recognized, and clinical and basic researches are constantly updating for their mechanisms of action. Here we summarize these research advances, which in turn helps us to understand the strategies and research directions of heart failure treatment

Key words:heart failure; cAMP; cGMP; PDE

Get Citation

Copy

Article Metrics

Abstract:
PDF:
HTML:
Cited by:

History

Received:November 04,2019
Revised:
Adopted:
Online: August 19,2020
Published:

Home

About this journal

Editorial Board

Info for Author

Contact Us

中文版

Get Citation

Share

Article Metrics

History

Article QR Code